2020 Virtual ESMO Review
2020 ESMO Update on Targeted Therapy in NSCLC: Can We Safely Combine Amivantamab + Lazertinib in Advanced EGFR+ Disease?
By
2020 Virtual ESMO Review
FEATURING
Ibiayi Dagogo-Jack
By
2020 Virtual ESMO Review
FEATURING
Ibiayi Dagogo-Jack
Login to view comments.
Click here to Login
